United States Kidney Cancer Therapeutics and Diagnostics Market Outlook to 2030: Size, Share, Growth and Trends

The United States Kidney Cancer Therapeutics and Diagnostics Market was valued at USD 5,530 Mn in 2024 on a manufacturer and service-provider revenue basis. This includes drug net sales and kidney-cancer-attributed diagnostic revenue, while excluding hospital facility fees and surgical procedure fees. The market is sizable because renal oncology combines high-value systemic therapies with repeated imaging, pathology, and laboratory monitoring over multiple care stages. Commercially, this means value is not captured only at treatment initiation; it is distributed across diagnosis, therapy selection, treatment monitoring, recurrence management, and survivorship follow-up.

The market is projected to grow from USD 5,530 Mn in 2024 to USD 7,830 Mn by 2030, implying a forecast CAGR of 6.0% for 2025-2030. This is slower than the 2019-2024 rebound-driven historical CAGR of 7.1%, but the forecast is higher quality because it is supported by richer treatment mix, broader adjuvant use, and rising precision-diagnostics content per patient. Growth is therefore expected to come from both more patients moving through care and higher revenue intensity per case as diagnostics and newer therapy lines gain weight.

The largest absolute profit pool remains targeted therapy, but the most important strategic shift is toward precision-linked revenue. Targeted Therapy accounted for USD 1,820 Mn in 2024, while Immuno-Oncology contributed USD 1,600 Mn; together they dominate current therapeutic economics. However, Molecular Diagnostics & Genomic Testing is the fastest-growing segment at 11.5% CAGR, indicating that future value creation will increasingly depend on identifying the right patient, sequencing the right regimen, and sustaining monitoring intensity. This shifts bargaining power toward firms with combined therapy, biomarker, and care-pathway integration capabilities.

The main downside risk is margin pressure from reimbursement scrutiny layered on top of operational bottlenecks. At the policy level, U.S. drug pricing oversight has intensified through the Medicare negotiation framework, increasing net-price sensitivity for high-cost oncology portfolios. Operationally, imaging and pathology capacity remains tight, which can delay diagnosis, therapy initiation, and follow-up monitoring. These pressures are especially relevant in a market where commercial success depends on repeated, coordinated touchpoints rather than a single dispensing event. The result is a risk profile that combines pricing compression with throughput friction.

The United States is the dominant North American market by a wide margin. Based on the locked sizing framework, the U.S. represented about 80.0% of North American market value in 2024, supported by the region's largest incident case base, deeper reimbursement architecture, and stronger clinical-trial and cancer-center infrastructure. This position matters because suppliers launching new renal oncology therapies or diagnostics can reach commercial scale faster in the United States than in adjacent markets. Regional leadership is therefore not only about size, but also about adoption speed and monetization depth.

The core demand driver is the interaction of disease burden with richer treatment pathways. Kidney cancer incidence remains significant in the United States, and a large living patient pool sustains follow-up imaging, laboratory monitoring, and later-line treatment. At the same time, regulatory expansion has broadened use cases across advanced and adjuvant settings, while NGS reimbursement supports higher-value therapy selection. This combination means growth is no longer just about more diagnoses; it is about more revenue captured per patient journey through precision diagnostics, combination therapy, and longer-duration management.